SCHEMBL1503287

SCHEMBL1503287

NC(=O)c1cnc(C(=O)N(O)Cc2ccc3c(c2)OCO3)c(O)c1CO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.41
HSP90AA1 P07900 1/20 0.40
AURKA O14965 2/20 0.39
RPS6KB1 P23443 2/20 0.39
AURKB Q96GD4 1/20 0.39
TDP1 Q9NUW8 1/20 0.37
KDM4E B2RXH2 3/20 0.37
GPR52 Q9Y2T5 1/20 0.37
TSHR P16473 2/20 0.37
FSHR P23945 1/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1503234 0.73 TSHR (0.39) MAPK8AURKARPS6KB1AURKBTDP1
SCHEMBL1503119 0.71 POLB (0.53) HSP90AA1ALDH1A1HSD17B10HDAC3HDAC1
SCHEMBL2219957 0.66 HDAC1 (0.54) HSP90AA1KDM4ECYP3A4ALDH1A1HSD17B10
SCHEMBL2219513 0.65 IGFBP3 (0.42) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL3722805 0.62 CYP3A4 (0.52) MAPK8GPR52CYP3A4ALDH1A1L3MBTL1
SCHEMBL6268216 0.62 MAPK1 (0.54) TDP1KDM4ETSHRALDH1A1L3MBTL1
SCHEMBL11428566 0.62 ALDH1A1 (0.53) TSHRCYP3A4CYP2D6ALDH1A1MAPT
SCHEMBL7391673 0.61 NPC1 (0.52) MAPK8AURKARPS6KB1AURKBKDM4E
SCHEMBL49914 0.61 CYP3A4 (0.65) CYP3A4CYP2D6ALDH1A1MAPTNPC1
SCHEMBL29907219 0.61 CYP3A4 (0.65) CYP3A4CYP2D6ALDH1A1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US claimed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US claimed
US-8742123-B2 HIV integrase inhibitors from pyridoxine TAIMED BIOLOGICS, INC. (TW) 2014-06-03 US disclosed
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA, INC. (CA) 2011-07-21 US disclosed
EP-2300433-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE Ambrilia Biopharma Inc. (CA) 2011-03-30 EP disclosed
WO-2009146555-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE AMBRILIA BIOPHARMA INC. (CA) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178120-A1 HIV INTEGRASE INHIBITORS FROM PYRIDOXINE PNPO, CCNB1, BLVRB MAPK8 3242/4885HSP90AA1 4730/4885AURKA 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.